Allogene Therapeutics
Clinical trials sponsored by Allogene Therapeutics, explained in plain language.
Clinical-stage biotech developing allogeneic CAR-T therapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Off-the-Shelf CAR t cells take on Hard-to-Treat myeloma
Disease control CompletedThis early-phase study tested a new type of CAR T cell therapy, called ALLO-715, made from donor cells (not the patient's own). It was given to 73 adults with multiple myeloma that had come back or stopped responding to at least three prior treatments. The goal was to check safet…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Off-the-Shelf CAR t cells take on tough lymphomas
Disease control CompletedThis early-phase study tested a new type of cell therapy called ALLO-501, made from donor cells rather than the patient's own cells, in 50 adults with lymphoma that had come back or stopped responding to treatment. The therapy targets CD19, a protein on cancer cells, and was give…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC